REHOVOT, Israel, June 14 /PRNewswire/ -- Rosetta Genomics and
Rockefeller University today announced the signing of a licensing agreement
that will allow Rosetta Genomics to access nearly 180 proprietary microRNAs
from Rockefeller University. These microRNAs will be added to Rosetta
Genomics's microRNA database, providing the company with additional
biomarker candidates for its diagnostic development programs. Under the
terms of the agreement, Rosetta Genomics will be able to use these
microRNAs to potentially advance multiple research development programs
targeting new microRNA based diagnostic tools for a variety of diseases.
"Being one of the first companies to focus on microRNAs, we see
ourselves as leaders in this field, and our filed patent applications cover
more than half of all biologically validated microRNAs of which we are
aware. This agreement positions us to apply our experience and expand our
development program further in the years ahead. We are now positioned to
target a broader range of promising development and commercial
opportunities in the microRNA arena," said Amir Avniel, president and CEO
of Rosetta Genomics.
Rosetta Genomics has developed a proprietary discovery process that has
led to the discovery of nearly 360 biologically validated human microRNAs.
The agreement with Rockefeller positions Rosetta Genomics to pursue
research based on 530 of the 660 publicly-confirmed microRNA genes in the
entire human genome. Under the terms of the agreement, Rosetta Genomics
will pay an initiation fee to Rockefeller University as well as maintenance
fees and royalties.
MicroRNAs (miRNAs) are recently discovered, naturally occurring small
RNAs that act as protein regulators and have the potential to be the basis
for a new class of diagnostics and therapeutics. Because many diseases are
caused by the misregulated activity of proteins, the ability to selectively
regulate protein activity through microRNAs could provide the means to
treat a wide range of human diseases. In addition, microRNAs have been
shown to have different expression levels in certain diseased versus normal
tissues. These differences potentially provide for a novel diagnostic
strategy for many diseases. MicroRNAs are thought to play a key role in the
differentiation of cells into specific cell types performing various
functions in the body. The recent discovery of microRNAs is recognized as a
major scientific breakthrough that has the potential to transform the
diagnosis, prevention and treatment of diseases.
About Rockefeller University
The Rockefeller University is a world-renowned center for research and
graduate education in the biomedical sciences, chemistry, and physics.
Founded by John D. Rockefeller in 1901, the university has been the site of
many important scientific breakthroughs. Rockefeller scientists established
that DNA is the chemical basis of heredity, discovered blood groups, showed
that viruses can cause cancer, founded the modern field of cell biology,
and worked out the structure of antibodies. Twenty-three Nobel Prize
winners have been associated with the university.
For more information please visit: http://www.rockefeller.edu
About Rosetta Genomics
Rosetta Genomics is a leader in the development of microRNA-based
diagnostics and therapeutics. Founded in 2000, the company's integrative
research platform combining bioinformatics and state-of-the-art laboratory
processes has led to the discovery of nearly 360 biologically validated
novel human microRNAs. Building on its strong IP position and strategic
alliances with leading biotechnology companies, Rosetta Genomics is working
to develop a full range of diagnostics and therapeutic products based on
microRNAs. The company's primary therapeutic focus is in the development of
microRNA-based products to diagnose and treat different forms of cancer.
SOURCE Rosetta Genomics